Drugs & Medicine Recalls

Pharmaceutical recall notices, chemical impurities, and biological contamination.

Showing 24 of 400 results
Pharmaceutical
FDA DrugsClass II

5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL free...

Lack of Assurance of Sterility

Apr 15, 2026Fresenius Kabi USA, LLC
Pharmaceutical
FDA DrugsClass II

Xanax XR, alprazolam, extended-release tablets, 3 mg, 60 Tablets bottles, Rx onl...

Failed Dissolution Specifications

Apr 15, 2026Viatris, Inc.
Pharmaceutical
FDA DrugsClass II

5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL free...

Lack of Assurance of Sterility

Apr 15, 2026Fresenius Kabi USA, LLC
Pharmaceutical
FDA DrugsClass II

Artificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol 0.5%, povidone 0...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

Prazosin Hydrochloride Capsules, USP, 5mg, 100-count bottle, Rx Only, Manufactur...

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Apr 8, 2026Appco Pharma LLC
Pharmaceutical
FDA DrugsClass II

Bromfenac Ophthalmic Solution 0.07%, 3 ml, Rx only, Sterile, Manufactured for: A...

Failed Impurities/Degradation Specifications: out of specification at the time of testing i.e. 20th month stability testing.

Apr 8, 2026ALEMBIC PHARMACEUTICALS, INC.
Pharmaceutical
FDA DrugsClass II

Prazosin Hydrochloride Capsules, USP, 2mg, 100-count bottle, Rx Only, Manufactu...

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Apr 8, 2026Appco Pharma LLC
Pharmaceutical
FDA DrugsClass II

Ultra Lubricating Eye Drops (polyethylene 400 0.4%, propylene glycol 0.3%), Ster...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

Dry Eye Relief Eye Drops, (glycerin 0.2%, hypromellose 0.2% and polyethylene gly...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

Sterile EYE DROPS REDNESS LUBRICANT (glycerin 0.25% and naphazoline HCl 0.012%),...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

EYE DROPS Advanced Relief, (dextran 70 0.1%, polyethylene glycol 400 1% and tetr...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

Sterile Eye Drops ORIGINAL FORMULA (tetrahydrozoline HCl 0.05%), 0.5 FL OZ (15mL...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

traMADol Hydrochloride Tablets, USP, 50 mg, 500-count bottles, Rx only, Manufac...

Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).

Apr 8, 2026Amneal Pharmaceuticals, LLC
Pharmaceutical
FDA DrugsClass II

STERILE EYE DROPS SOOTHING TEARS (polyethylene glycol 400 0.4% and propylene gly...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

Prazosin Hydrochloride Capsules, USP, 1mg, 100-count bottle, Rx Only, Manufactur...

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Apr 8, 2026Appco Pharma LLC
Pharmaceutical
FDA DrugsClass I

Magnesium Sulfate in Water for Injection, 4g/100 mL (40mg/mL) IV bag, further pa...

Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.

Apr 8, 2026Amneal Pharmaceuticals, LLC
Pharmaceutical
FDA DrugsClass II

Sterile EYE DROPS AC (tetrahydrozoline HCl 0.05%, zinc sulfate 0.25%), 0.5 fl. o...

Lack of Assurance of Sterility

Apr 8, 2026K.C. Pharmaceuticals, Inc
Pharmaceutical
FDA DrugsClass II

Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687...

Failed tablet specifications.

Apr 1, 2026Amerisource Health Services LLC
Pharmaceutical
FDA DrugsClass II

Levothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufact...

Subpotent Drug

Apr 1, 2026MACLEODS PHARMA USA, INC
Pharmaceutical
FDA DrugsClass II

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 ...

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Apr 1, 2026Teva Pharmaceuticals USA, Inc
Pharmaceutical
FDA DrugsClass II

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 ...

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Apr 1, 2026Teva Pharmaceuticals USA, Inc
Pharmaceutical
FDA DrugsClass II

CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial...

Lack of Assurance of Sterility

Apr 1, 2026Chiesi USA, Inc.
Pharmaceutical
FDA DrugsClass III

Gelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empt...

Failed Tablet/Capsule Specifications

Apr 1, 2026Radnostix
Pharmaceutical
FDA DrugsClass II

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 ...

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Apr 1, 2026Teva Pharmaceuticals USA, Inc